drugset / Trial / NCT04447235
Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection
RandomizedParallel-groupDouble-blindTreatment
Summary
Ivermectin plus losartan as prophilaxy to severe events in patients with cancer with recent diagnosis of COVID-19
Timeline
- Start
- 2020-07-23
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivermectin | Small molecule | 12 mg | — |
| Subject | Losartan | Other / unclassified | 50 mg | Oral |